Refractory Idiopathic Infantile Pyoderma Gangrenosum Successfully Treated With Infliximab: A Case Report.
- 1Department of Pediatrics Asahikawa Medical University Asahikawa Hokkaido Japan asahikawa-med.ac.jp.
- 2Department of Dermatology Asahikawa Medical University Asahikawa Hokkaido Japan asahikawa-med.ac.jp.
Abstract
Pyoderma gangrenosum (PG) is a noninfectious neutrophilic dermatosis that can occur either idiopathically or secondary to various systemic conditions. PG is rare in childhood and even rarer in infancy. Due to its rarity, the pathophysiological mechanisms remain unclear. Although systemic glucocorticoids are considered the first-line therapy, no standardized second-line or subsequent therapeutic approach has been established, particularly for refractory cases. In this report, we present a case of infantile idiopathic PG showing sustained clinical improvement after the addition of the anti-tumor necrosis factor (TNF)-alpha antibody infliximab (IFX). In addition, we conducted multiplex cytokine analysis to explore the patient's inflammatory profile and provide preliminary observations regarding the inflammatory milieu associated with this condition. The patient, a 9-month-old infant, developed multiple pustules and ulcerative skin lesions on the face and extremities following Bacillus Calmette-Guérin (BCG) vaccination. Pathogen investigations were all negative, and the diagnosis of PG was made based on clinical findings, supported by histological features and exclusion of other conditions. After initial treatment with glucocorticoids and cyclosporine, remission was achieved; however, repeated relapses occurred. IFX was subsequently initiated, resulting in significant clinical improvement. Serum cytokine profiling at the onset revealed a broad elevation of proinflammatory cytokines, including soluble TNF receptors 1 and 2, with a pattern partially overlapping with that observed in Kawasaki disease. The clinical course and cytokine analysis results suggest that IFX may be a viable treatment option for refractory PG, even in infants.
Related
- Super-Refractory Status Epilepticus (SRSE) Secondary to Neurosyphilis Complicated by a Prolonged Drug-Induced Cardiac Arrest Successfully Bridged With Extracorporeal Membrane Oxygenation (ECMO) and Impella®: A Case Report.
- A comparative analysis of semiannual versus annual rituximab maintenance in patients with refractory idiopathic inflammatory myopathies: a retrospective longitudinal real-world study.
- Incidence, Prevalence and Diagnostic Delay in Pyoderma Gangrenosum: A Finnish Nationwide Registry-based Study.
- Pyoderma gangrenosum chez une femme de 26 ans.
- Successful Treatment of Recalcitrant Pyoderma Gangrenosum with Baricitinib in Two Patients with Rheumatoid Arthritis.
BibTeX
@article{kurisawa2026refractory,
title = {{Refractory Idiopathic Infantile Pyoderma Gangrenosum Successfully Treated With Infliximab: A Case Report.}},
author = {Mio June Kurisawa and Tsunehisa Nagamori and Masayuki Sato and Emi Ishibazawa and Junki Tsuda and Mari Kishibe and Satoru Takahashi},
journal = {Case reports in pediatrics},
year = {2026},
month = oct,
doi = {10.1155/crpe/2259894},
url = {https://europepmc.org/article/MED/42923922},
note = {CC BY},
}
RIS
TY - JOUR
TI - Refractory Idiopathic Infantile Pyoderma Gangrenosum Successfully Treated With Infliximab: A Case Report.
AU - Mio June Kurisawa
AU - Tsunehisa Nagamori
AU - Masayuki Sato
AU - Emi Ishibazawa
AU - Junki Tsuda
AU - Mari Kishibe
AU - Satoru Takahashi
PY - 2026
DA - 2026/10/22
JO - Case reports in pediatrics
DO - 10.1155/crpe/2259894
UR - https://europepmc.org/article/MED/42923922
AB - Pyoderma gangrenosum (PG) is a noninfectious neutrophilic dermatosis that can occur either idiopathically or secondary to various systemic conditions. PG is rare in childhood and even rarer in infancy. Due to its rarity, the pathophysiological mechanisms remain unclear. Although systemic glucocorticoids are considered the first-line therapy, no standardized second-line or subsequent therapeutic approach has been established, particularly for refractory cases. In this report, we present a case of infantile idiopathic PG showing sustained clinical improvement after the addition of the anti-tumor necrosis factor (TNF)-alpha antibody infliximab (IFX). In addition, we conducted multiplex cytokine analysis to explore the patient's inflammatory profile and provide preliminary observations regarding the inflammatory milieu associated with this condition. The patient, a 9-month-old infant, developed multiple pustules and ulcerative skin lesions on the face and extremities following Bacillus Calmette-Guérin (BCG) vaccination. Pathogen investigations were all negative, and the diagnosis of PG was made based on clinical findings, supported by histological features and exclusion of other conditions. After initial treatment with glucocorticoids and cyclosporine, remission was achieved; however, repeated relapses occurred. IFX was subsequently initiated, resulting in significant clinical improvement. Serum cytokine profiling at the onset revealed a broad elevation of proinflammatory cytokines, including soluble TNF receptors 1 and 2, with a pattern partially overlapping with that observed in Kawasaki disease. The clinical course and cytokine analysis results suggest that IFX may be a viable treatment option for refractory PG, even in infants.
SN - 2090-6803
SN - 2090-6811
ER -